Long-term use of angiotensin II receptor blockers and risk of cancer: A population-based cohort analysis

International Journal of Cardiology

Volumn 167, Issue 5, 2013, Pages 2162-2166

  Wang, Kang Ling ^a,b   Liu, Chia Jen ^a   Chao, Tze Fan ^a,b   Huang, Chi Ming ^a,b   Wu, Cheng Hsueh ^a,b   Chen, Tzeng Ji ^a,b   Chiang, Chern En ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Angiotensin II receptor blockers; Cohort study; Risk of cancer

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; COLON CANCER; COMORBIDITY; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FEMALE; FOLLOW UP; HUMAN; LIVER CANCER; LONG TERM CARE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; RISK ASSESSMENT; RISK REDUCTION; STOMACH CANCER; TREATMENT INDICATION; TREATMENT OUTCOME;

ANGIOTENSIN II RECEPTOR BLOCKERS; COHORT STUDY; RISK OF CANCER;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASMS; POPULATION SURVEILLANCE; RISK FACTORS; TAIWAN; TIME FACTORS;

EID: 84883309558     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.05.096     Document Type: Article

References (25)

1. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, and J.L. Izzo Jr Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
2. G. Mancia, B.G. De, A. Dominiczak, R. Cifkova, R. Fagard, and G. Germano 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 25 2007 1105 1187
3. D.A. Duprez Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review J Hypertens 24 2006 983 991
4. G.R. Smith, and S. Missailidis Cancer, inflammation and the AT1 and AT2 receptors J Inflamm (Lond) 1 2004 3
5. E. Escobar, T.S. Rodriguez-Reyna, O. Arrieta, and J. Sotelo Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer Curr Vasc Pharmacol 2 2004 385 399
6. F. Deshayes, and C. Nahmias Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16 2005 293 299
7. A.F. Lever, D.J. Hole, C.R. Gillis, I.R. McCallum, G.T. McInnes, and P.L. MacKinnon Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352 1998 179 184
8. S. Friis, H.T. Sorensen, L. Mellemkjaer, J.K. McLaughlin, G.L. Nielsen, and W.J. Blot Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark Cancer 92 2001 2462 2470
9. M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J. McMurray, and E.L. Michelson Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 2003 759 766
10. I. Sipahi, S.M. Debanne, D.Y. Rowland, D.I. Simon, and J.C. Fang Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials Lancet Oncol 11 2010 627 636
11. S. Bangalore, S. Kumar, S.E. Kjeldsen, H. Makani, E. Grossman, and J. Wetterslev Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324?168 participants from randomised trials Lancet Oncol 12 2011 65 82
12. T.A.T. Collaboration Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals J Hypertens 29 2011 623 635
13. R. Sugiura, H. Ogawa, T. Oka, R. Koyanagi, and N. Hagiwara Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy) Am J Cardiol 109 2012 576 580
14. B. Pasternak, H. Svanstrom, T. Callreus, M. Melbye, and A. Hviid Use of Angiotensin Receptor Blockers and the Risk of Cancer Circulation 123 2011 1729 1736
15. G. Opelz, and B. Dohler Treatment of kidney transplant recipients with ACEi/ARB and risk of respiratory tract cancer: a collaborative transplant study report Am J Transplant 11 2011 2483 2489
16. C.-C. Huang, W.-L. Chan, Y.-C. Chen, T.-J. Chen, S.-J. Lin, and J-W Chen Angiotensin II Receptor Blockers and Risk of Cancer in Patients With Systemic Hypertension Am J Cardiol 107 2011 1028 1033
17. C.-H. Chang, J.-W. Lin, L.-C. Wu, and M.-S. Lai Angiotensin Receptor Blockade and Risk of Cancer in Type 2 Diabetes Mellitus: A Nationwide Case-control Study J Clin Oncol 29 2011 3001 3007
18. G. Mancia Angiotensin receptor antagonists and increased risk of cancer. Further evidence against J Hypertens 29 2011 653 654
19. T.L. Assimes, and S. Suissa Immortal person time bias in pharmacoepidemiological studies of antihypertensive drugs Am J Cardiol 108 2011 902 903
20. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
21. P. Boyle, and J. Ferlay Cancer incidence and mortality in Europe, 2004 Ann Oncol 16 2005 481 488
22. J. LeLorier, G. Gregoire, A. Benhaddad, J. Lapierre, and F. Derderian Discrepancies between meta-analyses and subsequent large randomized, controlled trials N Engl J Med 337 1997 536 542
23. J.L. Tang, and J.L. Liu Misleading funnel plot for detection of bias in meta-analysis J Clin Epidemiol 53 2000 477 484
24. H. Jick, S. Jick, L.E. Derby, C. Vasilakis, M.W. Myers, and C.R. Meier Calcium-channel blockers and risk of cancer Lancet 349 1997 525 528
25. A.A. Alsheikh-Ali, P.V. Maddukuri, H. Han, and R.H. Karas Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials J Am Coll Cardiol 50 2007 409 418